There is a great deal of emphasis on streamlining the regulatory process to get important drugs to subjects who need them expeditiously. This is of increasing importa...

Declining healthcare spending combined with increased pressure on the HC system budget is creating an incentive for patients to consent to new treatments, and fosteri...

Since 2007, new drugs need a paediatric investigation plan (PIP) for EU registration. Without a PIP accepted by the European Medicines Agency (EMA)'s paediatric commi...

The importance of ensuring an accurate diagnosis of progressive supranuclear palsy (PSP) is critical for the development of effective disease-modifying therapies that...

IRT systems are commonly credited with helping to ensure that the right drug gets to the right patient at the right time. This digital side of the supply chain suppor...

Peter Muller, Managing Director, Schlafender Hase, Americas, says “Bringing a new drug to market costs millions, so it’s highly risky to leave product labelling and p...